KP-301 / Mirador Therapeutics, Jasper Therapeutics - LARVOL DELTA

Mirador Therapeutics…announced that it has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals (Kira) for KP-301, a potentially long-acting, sweeping anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation, and other related intellectual property (Businesswire) - "Mirador plans to initiate a Phase 1 study of KP-301 by year-end 2026 and a Phase 2 AAV study in the first half of 2027, and to pursue monotherapy and combination expansion into additional inflammatory disease indications....Under the terms of the agreement, Mirador receives exclusive worldwide rights to develop, manufacture and commercialize KP-301 across all indications. Kira will receive $12 million upon signing and is eligible to receive development and sales milestone payments....The addition of KP-301 reflects a Mirador360-driven approach to building a broad I&I portfolio, with multiple clinical readouts anticipated by year-end 2027."

Clinical data • Licensing / partnership • New trial • ANCA Vasculitis • Immunology • Inflammation